Mandate

Vinge advises Air Liquide Santé International on the acquisition of NordicInfu Care AB

March 11, 2013

Vinge is advising Air Liquide Santé International in connection with its acquisition of NordicInfu Care AB. Air Liquide Santé International is Europe’s leading and the world’s third largest company within home healthcare and provides treatment for patients with chronic diseases, such as Parkinson, COPD (Chronic Obstructive Pulmonary Disease) and diabetes. Air Liquide Santé International posted revenues of EUR 2.5 billion in 2012 and has 10,000 employees. Air Liquide Santé International is a division within the publicly listed French group Air Liquide.

NordicInfu Care AB is a leading company in the Nordic countries within home infusion therapy for patients with chronic diseases such as Parkinson, PAH (Pulmonary Arterial Hypertension) and diabetes and had a turnover in 2012 of approximately EUR 22 million. Through the acquisition, Air Liquide Santé International expands its home healthcare activities to the Nordic market, where presence up until now has been limited.

The Vinge team advising Air Liquide Santé International includes partner Jesper Ottergren and associate Ida Christiansson. Furthermore, among others, associates Lynn Andersson Wall and Charlotta Cronér (employment law), Rickard Vernet (competition law), Johan Cederblad (regulatory matters) and counsel Maria Schultzberg (tax) have assisted in the transaction.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025